Despite current therapeutics and interventions, pain continues to pose a significant burden on a global scale. There are an estimated 100 million people living with chronic pain in the U.S., which is more than cancer, diabetes and heart disease combined, and approximately one quarter of these people live with daily, severe pain.
We are passionate and committed to addressing the substantial and growing chronic pain epidemic. We are advancing one of the largest, exclusively pain-focused pipelines of novel, non-opioid therapies in active development in order to bridge the safety and efficacy gaps in current chronic pain treatment. We aim to ease the burden moderate to severe chronic pain places on patients and our healthcare system.
http://www.painmed.org/patientcenter/facts_on_pain.aspx, Last accessed December 21, 2017Learn More
Our company is led by a seasoned team of biotech and pharmaceutical executives with vast expertise in clinical development, commercial operations and business development, and an impressive and proven track record of developing and commercializing new safe and effective therapeutics.Meet Us
We’re redefining the study of pain therapies by using a three-pronged approach: 1) big data analytics to reveal the pain pathways where our analgesics will have the maximum therapeutic effect, 2) translational science to validate the safety and efficacy of our therapies in companion animals with the same naturally-occurring chronic pain conditions as humans and 3, more efficient early-stage clinical trial strategies to inform and de-risk development.Learn More
Our pipeline consists of novel, non-opioid pain treatment therapeutics that are in development potentially to treat a broad array of chronic pain indications, including neuropathic, inflammatory and mixed pain (e.g., chronic back pain), without the risks of dependence or abuse. We believe that our pipeline is uniquely positioned to address the limitations of currently available therapies by providing safe, effective and long-term pain treatment solutions.Learn More
We are currently advancing several promising pipeline candidates for the treatment of an array of moderate to severe chronic pain conditions.Learn More
Jan. 16, 2018Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain On January 16, Centrexion Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to CNTX-4975 for the treatment of pain associated with knee osteoarthritis.Learn More